Dr. Nimish Patel

Infectious Diseases Outcomes Research

patel's picture
Nimish Patel, Pharm.D., Ph.D., AAHIVP

Associate Professor of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences

(858) 822-3561
Research Summary

Dr. Nimish Patel's main research interest involves evaluating clinical outcomes associated with anti-infective medications. Dr. Patel's research encompasses three domains: 1) comparative safety and effectiveness of antimicrobials in real-world settings, 2) predictors and outcomes of patients with contraindicated drug-drug interactions and 3) pharmacoeconomic strategies of emerging antimicrobial agents that result in a cost savings relative to existing medications associated with a high frequency of costly toxicities or prolonged hospitalization. Most of Dr. Patel's research occurs within the Veterans Healthcare Administration or involves other large sources of data. Dr. Patel's clinical areas of expertise are treatment of hospitalized patients with infectious diseases, pharmacokinetic monitoring of antimicrobials, antibiotic stewardship, HIV consult service and hepatitis C. Some of his current research projects include: real-world safety and effectiveness of fluoroquinolones versus ceftriaxone/azithromycin for patients with community acquired pneumonia, early use fidaxomicin versus oral vancomycin among patients with C. difficile infections and predictors of drug-drug interactions among patients infected with HIV and hepatitis C and effect of exogenous hormones on renal function and drug concentrations in transgender patients using pre-exposure prophylaxis.

Academic Achievements


Pharm.D., Albany College of Pharmacy & Health Sciences (2006); Pharmacy Residency in HIV Pharmacotherapy, University of Toronto/University Health Network – Toronto General Hospital Immunodeficiency Clinic and McGill University Health Centre – Montreal Chest Institute (2007); Fellowship in Infectious Diseases Outcomes Research, Albany College of Pharmacy & Health Sciences (2010); M.S. Epidemiology, University at Albany – State University of New York (2010); American Academy of HIV Medicine Pharmacist Credentialing (2012); Ph.D. Epidemiology, University at Albany – State University of New York (2014).

Awards and Honors:

Faculty Preceptor of the Year at ACPHS. (2012); Teacher of the Year at ACPHS (2012), Society of Infectious Diseases Pharmacists (SIDP) Young Investigator Research Award (2014); Janis V. Giorgi Memorial Award – California HIV/AIDS Research Program (2019).

Leadership Experience:

Journal reviewer for J of Antimicrob Chemother, Diag Microbiol and Infect Dis, Infect Dis and Therapy, Antimicrob Agents and Chemother, Pharmacotherapy, and Am J Health-Sys Pharm

  • Therapeutics IV (SPPS 212D)
  • Clinical Research Design & Application (SPPS 208)
Key Contributions
  • Real world effectiveness and safety of antimicrobials for vancomycin-resistant Enterococcal bacteremia.
  • Predictors of drug-drug interactions among Veterans living with HIV and hepatitis C
Selected Publications
  • Maskarinec SA, Park LP, Ruffin F, Turner NA, Patel N, Eichenberger EM, van Duin D, Lodise T, Fowler VG Jr, Thaden JT. Positive follow-up blood cultures identify high mortality risk among patients with Gram-negative bacteraemia. Clin Microbiol Infect. 2020 Jul;26(7):904-910. doi: 10.1016/j.cmi.2020.01.025. Epub 2020 Feb 28. 
  • Ahmed A, Schriever C, Britt NS, Yager JL, Amin R, McGuey L, Patel N. Comparing Drug Interaction Frequencies of Various Hepatitis C Treatment Regimens among Monoinfected Patients. Ann Hepatol. 2019 Jul-Aug;18(4):601-606. doi: 10.1016/j.aohep.2019.01.005. Epub 2019 May 4. 
  • Sangiovanni R, Jakeman BJ, Nasiri M, Ruth L, Mahatme S, Patel N. Relationship between Contraindicated Drug-Drug Interactions and Subsequent Hospitalizations among HIV-infected Patients Initiating Combination Antiretroviral Therapy. AIDS Res Hum Retroviruses. 2019 May;35(5):430-433. doi: 10.1089/AID.2018.0205. Epub 2019 Feb 27.
  • Patel N et al. (2018) Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. Clin Drug Investig. 2018 Oct;38(10):935-943.
  • Bidell MR et al. (2018) Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins. J Antimicrob Chemother. 2018 Oct 1;73(10):2643-2651.
  • Patel N et al. (2018) Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. Am J Health Syst Pharm. 2018 Aug 1;75(15):1132-1139.
  • Yager JL et al (2017). Relationship Between Single Tablet Antiretroviral Regimen and Adherence to Antiretroviral and Non-Antiretroviral Medications Among Veterans' Affairs Patients with Human Immunodeficiency Virus. AIDS Patient Care STDS. 2017 Sep;31(9):370-376.
  • Britt NS et al (2017). Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Clin Infect Dis. 2017 Mar 1;64(5):605-613.
  • Jakeman B et al. (2017) Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients. Ann Pharmacother. 2017 May;51(5):365-372.
Potential Collaborative Programs
  • Investigator-initiated research grants assessing real-world safety and effectiveness of anti-infective agents used among Veterans Affairs patients with infectious diseases
  • Investigator-initiated research grants assessing frequency and predictors of contraindicated drug-drug interactions among patients with HIV and hepatitis C